Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""CTLA-4"" wg kryterium: Temat


Tytuł :
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.
Autorzy :
Prakadan SM; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute, Harvard University, Massachusetts Institute of Technology, & Massachusetts General Hospital, Cambridge, MA, USA.
Alvarez-Breckenridge CA; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Neurosurgery, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Markson SC; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Division of Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kim AE; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Klein RH; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Division of Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nayyar N; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Navia AW; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute, Harvard University, Massachusetts Institute of Technology, & Massachusetts General Hospital, Cambridge, MA, USA.
Kuter BM; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Kolb KE; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute, Harvard University, Massachusetts Institute of Technology, & Massachusetts General Hospital, Cambridge, MA, USA.
Bihun I; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Mora JL; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Bertalan MS; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Shaw B; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
White M; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Kaplan A; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Stocking JH; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Wadsworth MH 2nd; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA.; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Ragon Institute, Harvard University, Massachusetts Institute of Technology, & Massachusetts General Hospital, Cambridge, MA, USA.
Lee EQ; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chukwueke U; Division of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Wang N; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Subramanian M; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Rotem D; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.
Cahill DP; Department of Neurosurgery, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.
Adalsteinsson VA; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA.
Miller JW; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.
Sullivan RJ; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Carter SL; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA. .; Division of Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. .; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA. .
Brastianos PK; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA. .; Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA, USA. .; Massachusetts General Hospital Cancer Center, Boston, MA, USA. .
Shalek AK; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. .; Institute for Medical Engineering & Science, Massachusetts Institute of Technology, Cambridge, MA, USA. .; Broad Institute, Harvard University & Massachusetts Institute of Technology, Cambridge, MA, USA. .; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. .; Ragon Institute, Harvard University, Massachusetts Institute of Technology, & Massachusetts General Hospital, Cambridge, MA, USA. .; Division of Health Science & Technology, Harvard Medical School, Cambridge, MA, USA. .; Program in Computational & Systems Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Oct 12; Vol. 12 (1), pp. 5955. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain Neoplasms/*drug therapy
CTLA-4 Antigen/*immunology
Immune Checkpoint Inhibitors/*therapeutic use
Meningeal Carcinomatosis/*drug therapy
Meningeal Neoplasms/*drug therapy
Programmed Cell Death 1 Receptor/*immunology
Tumor Microenvironment/*drug effects
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Brain Neoplasms/immunology ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/pathology ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; Cell-Free Nucleic Acids/genetics ; Cell-Free Nucleic Acids/immunology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunotherapy ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Ipilimumab/therapeutic use ; Male ; Meningeal Carcinomatosis/immunology ; Meningeal Carcinomatosis/mortality ; Meningeal Carcinomatosis/pathology ; Meningeal Neoplasms/immunology ; Meningeal Neoplasms/mortality ; Meningeal Neoplasms/pathology ; Middle Aged ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/genetics ; Single-Cell Analysis ; Survival Analysis ; Tumor Microenvironment/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype.
Autorzy :
Shokrgozar N; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Karimi M; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Golmoghaddam H; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Rezaei N; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Moayed V; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sharifzadeh S; Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Arandi N; Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Oct; Vol. 100 (10), pp. 2463-2469. Date of Electronic Publication: 2021 Jul 29.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, CD/*genetics
CTLA-4 Antigen/*genetics
Hepatitis A Virus Cellular Receptor 2/*genetics
beta-Thalassemia/*genetics
Adolescent ; Adult ; Antigens, CD/immunology ; CTLA-4 Antigen/immunology ; Case-Control Studies ; Female ; Gene Expression ; Hepatitis A Virus Cellular Receptor 2/immunology ; Humans ; Isoantibodies/immunology ; Male ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; Young Adult ; beta-Thalassemia/immunology
Czasopismo naukowe
Tytuł :
Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Autorzy :
Kulikowska de Nałęcz A; Hematology and Hematological Oncology Department, Provincial Hospital, 45-372 Opole, Poland.
Ciszak L; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Usnarska-Zubkiewicz L; Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Frydecka I; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Pawlak E; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Szmyrka M; Department of Rheumatology and Internal Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Kosmaczewska A; Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 27; Vol. 22 (17). Date of Electronic Publication: 2021 Aug 27.
Typ publikacji :
Journal Article
MeSH Terms :
Gene Expression Regulation, Neoplastic*
CD4-Positive T-Lymphocytes/*immunology
CTLA-4 Antigen/*metabolism
Lymphocyte Activation/*immunology
Multiple Myeloma/*mortality
Programmed Cell Death 1 Receptor/*metabolism
Receptors, Immunologic/*metabolism
Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Tolerance/immunology ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/metabolism ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/mortality ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/genetics ; Receptors, Immunologic/antagonists & inhibitors ; Receptors, Immunologic/genetics ; Survival Rate ; T-Lymphocytes, Regulatory/immunology ; Th17 Cells/immunology
Czasopismo naukowe
Tytuł :
Differential Response of MDA-MB-231 and MCF-7 Breast Cancer Cells to In Vitro Inhibition with CTLA-4 and PD-1 through Cancer-Immune Cells Modified Interactions.
Autorzy :
Grubczak K; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Kretowska-Grunwald A; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Groth D; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Poplawska I; Department of Medical Pathomorphology, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Eljaszewicz A; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Bolkun L; Department of Haematology, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland.
Starosz A; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Holl JM; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.
Mysliwiec M; Department of Oncology, Medical University of Bialystok, Ogrodowa 12, 15-027 Bialystok, Poland.
Kruszewska J; Department of Oncology, Medical University of Bialystok, Ogrodowa 12, 15-027 Bialystok, Poland.
Wojtukiewicz MZ; Department of Oncology, Medical University of Bialystok, Ogrodowa 12, 15-027 Bialystok, Poland.
Moniuszko M; Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Jerzego Waszyngtona 13, 15-269 Bialystok, Poland.; Department of Allergology and Internal Medicine, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland.
Pokaż więcej
Źródło :
Cells [Cells] 2021 Aug 10; Vol. 10 (8). Date of Electronic Publication: 2021 Aug 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*immunology
Leukocytes, Mononuclear/*metabolism
Programmed Cell Death 1 Receptor/*immunology
Adult ; Antibodies/immunology ; B7-1 Antigen/metabolism ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; CTLA-4 Antigen/metabolism ; Cell Cycle Checkpoints ; Cell Line, Tumor ; Cell Proliferation ; Coculture Techniques ; Female ; Granzymes/metabolism ; Humans ; Interferon-gamma/metabolism ; Interleukin-10/metabolism ; Leukocytes, Mononuclear/cytology ; Leukocytes, Mononuclear/immunology ; MCF-7 Cells ; Perforin/metabolism ; Programmed Cell Death 1 Receptor/metabolism
Czasopismo naukowe
Tytuł :
Tim-3/CTLA-4 pathways regulate decidual immune cells-extravillous trophoblasts interaction by IL-4 and IL-10.
Autorzy :
Li M; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Sun F; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Qian J; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Chen L; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Li D; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Wang S; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Du M; Laboratory for Reproductive Immunology, Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, P.R. China.
Pokaż więcej
Źródło :
FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Aug; Vol. 35 (8), pp. e21754.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*immunology
Decidua/*immunology
Hepatitis A Virus Cellular Receptor 2/*immunology
Interleukin-10/*immunology
Interleukin-4/*immunology
Trophoblasts/*immunology
Animals ; CTLA-4 Antigen/antagonists & inhibitors ; Cell Communication/immunology ; Cells, Cultured ; Decidua/cytology ; Embryo Loss/immunology ; Female ; Hepatitis A Virus Cellular Receptor 2/antagonists & inhibitors ; Humans ; Immune Tolerance ; Interleukin-10/administration & dosage ; Interleukin-4/administration & dosage ; Male ; Maternal-Fetal Exchange/immunology ; Mice, Inbred BALB C ; Mice, Inbred CBA ; Mice, Inbred DBA ; Models, Immunological ; Placentation/immunology ; Pregnancy ; Pregnancy Outcome ; Signal Transduction/immunology ; Trophoblasts/cytology
Czasopismo naukowe
Tytuł :
Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Autorzy :
Lanz AL; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Riester M; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Peters P; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Schwerd T; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Lurz E; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Hajji MS; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Rohlfs M; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Ley-Zaporozhan J; Department of Radiology, Pediatric Radiology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Walz C; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Munich, Germany.
Kotlarz D; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Klein C; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Infection Research (DZIF), Munich, Germany; Munich Centre for Rare Diseases (M-ZSE), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Albert MH; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Hauck F; Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Infection Research (DZIF), Munich, Germany; Munich Centre for Rare Diseases (M-ZSE), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany. Electronic address: .
Pokaż więcej
Źródło :
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2021 Aug; Vol. 229, pp. 108779. Date of Electronic Publication: 2021 Jun 08.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Abatacept/*therapeutic use
CTLA-4 Antigen/*deficiency
Immunosuppressive Agents/*therapeutic use
Adolescent ; CTLA-4 Antigen/genetics ; CTLA-4 Antigen/immunology ; Female ; Haploinsufficiency/genetics ; Haploinsufficiency/immunology ; Hematopoietic Stem Cell Transplantation ; Humans ; Immune System Diseases/genetics ; Immune System Diseases/immunology ; Immune System Diseases/therapy ; Male ; Mutation, Missense ; T-Lymphocytes, Regulatory/immunology
Czasopismo naukowe
Tytuł :
A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects.
Autorzy :
Wang W; International Nanobody Research Center of Guangxi, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, China.; Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, 570100, Hainan, China.; Department of traditional Chinese medicine, The First Affiliated Hospital of Hainan Medical College, Haikou, 570100, Hainan, China.
Wang X; Department of Anesthesiology, Tunchang people's Hospital, Tunchang, 571600, Hainan, China.
Yang W; Department of Anatomy, Zunyi Medical University, Zunyi, 563006, China.
Zhong K; Department of acupuncture and moxibustion, Hainan General Hospital, The Affiliated Hainan Hospital of Hainan Medical University, Haikou, 570100, Hainan, China.
He N; Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, 570100, Hainan, China.
Li X; Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou, 570100, Hainan, China.
Pang Y; Department of traditional Chinese medicine, The First Affiliated Hospital of Hainan Medical College, Haikou, 570100, Hainan, China.
Lu Z; Department of Laboratory Medicine, The second affiliated hospital of Hainan medical university, Haikou, 570311, Hainan, China.
Liu A; International Nanobody Research Center of Guangxi, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, China. .; Affiliated Tumor Hospital, Guangxi Medical University, Nanning, 530021, Guangxi, China. .
Lu X; International Nanobody Research Center of Guangxi, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Sep 15; Vol. 21 (1), pp. 1029. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :
Journal Article
MeSH Terms :
CTLA-4 Antigen/*antagonists & inhibitors
Cytokine-Induced Killer Cells/*immunology
Dendritic Cells/*immunology
Immune Tolerance/*immunology
Single-Domain Antibodies/*pharmacology
Animals ; CTLA-4 Antigen/immunology ; Cell Proliferation ; Coculture Techniques ; Cytokine-Induced Killer Cells/drug effects ; Dendritic Cells/drug effects ; Female ; Hep G2 Cells ; Heterografts ; Humans ; Immunotherapy, Adoptive/methods ; Inflammation Mediators/metabolism ; Interferon-gamma/biosynthesis ; Interleukin-10/metabolism ; Interleukin-2/metabolism ; Leukocytes, Mononuclear/immunology ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Neoplasm Transplantation ; Single-Domain Antibodies/immunology ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
A single homogeneous assay for simultaneous measurement of bispecific antibody target binding.
Autorzy :
Christian EA; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: .
Hussmann GP; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Babu M; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Prophet M; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Mazor Y; Department of Antibody Discovery and Protein Engineering, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Chen W; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Grigoriadou C; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Lin S; Department of Analytical Sciences, BioPharmaceuticals Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Pokaż więcej
Źródło :
Journal of immunological methods [J Immunol Methods] 2021 Sep; Vol. 496, pp. 113099. Date of Electronic Publication: 2021 Jul 02.
Typ publikacji :
Journal Article
MeSH Terms :
Antibody Specificity*
Immunoassay*
Antibodies, Bispecific/*immunology
Antigens/*immunology
CTLA-4 Antigen/*immunology
Programmed Cell Death 1 Receptor/*immunology
Antibodies, Bispecific/metabolism ; Antigen-Antibody Complex ; Antigens/metabolism ; Binding Sites, Antibody ; Buffers ; CTLA-4 Antigen/metabolism ; Enzyme-Linked Immunosorbent Assay ; Epitopes ; Humans ; Hydrogen-Ion Concentration ; Kinetics ; Predictive Value of Tests ; Programmed Cell Death 1 Receptor/metabolism ; Protein Binding ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
The role of cytotoxic T-Lymphocyte antigen-4+49A/G gene polymorphism in cutaneous leishmaniasis.
Autorzy :
Al-Ghabban MJS; Department of Biology, College of Education for Pure Sciences, University of Diyala, Iraq. Electronic address: .
Al-Bayati NY; Department of Microbiology, College of Medicine, University of Diyala, Iraq. Electronic address: .
Al-Mayah QS; Medical Research Unit, College of Medicine, Al-Nahrain University, Iraq. Electronic address: .
Al-Matubsi HY; Department of Pharmacology and Medical Sciences, University of Petra, Amman, Jordan. Electronic address: .
Pokaż więcej
Źródło :
Microbial pathogenesis [Microb Pathog] 2021 Sep; Vol. 158, pp. 105073. Date of Electronic Publication: 2021 Jun 25.
Typ publikacji :
Journal Article
MeSH Terms :
CTLA-4 Antigen*/genetics
Leishmaniasis, Cutaneous*/genetics
Case-Control Studies ; Cross-Sectional Studies ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Humans ; Polymorphism, Single Nucleotide
Czasopismo naukowe
Tytuł :
Quantum binding energies of checkpoint CTLA-4 in complex with the immuno-oncological drug ipilimumab.
Autorzy :
Tavares ABMLA; Departamento de Bioquímica, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. ínicas, Universidade Federal de Pernambuco, 50.670-901, Recife-PE, Brazil.
Albuquerque EL; Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. .
Pokaż więcej
Źródło :
Physical chemistry chemical physics : PCCP [Phys Chem Chem Phys] 2021 Jul 28; Vol. 23 (29), pp. 15620-15627.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*chemistry
CTLA-4 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*chemistry
Ipilimumab/*chemistry
Amino Acid Sequence ; Antineoplastic Agents, Immunological/pharmacology ; CTLA-4 Antigen/chemistry ; Drug Screening Assays, Antitumor ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Ipilimumab/pharmacology ; Models, Molecular ; Protein Binding ; Protein Conformation ; Thermodynamics
Czasopismo naukowe
Tytuł :
Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade.
Autorzy :
Dai X; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Bu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Gao Y; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Guo J; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Hu J; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Jiang C; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Zhang Z; Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Xu K; Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Duan J; Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
He S; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Zhang J; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Wan L; Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Liu T; Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Zhou X; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hung MC; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address: .
Wei W; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Jun 03; Vol. 81 (11), pp. 2317-2331.e6. Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Immune Checkpoint Inhibitors*
AMP-Activated Protein Kinases/*genetics
B7-H1 Antigen/*genetics
Breast Neoplasms/*genetics
CTLA-4 Antigen/*genetics
Colorectal Neoplasms/*genetics
AMP-Activated Protein Kinases/immunology ; Allografts ; Animals ; Antibodies, Neutralizing/pharmacology ; Antineoplastic Agents/pharmacology ; B7-H1 Antigen/immunology ; Biphenyl Compounds/pharmacology ; Breast Neoplasms/immunology ; Breast Neoplasms/mortality ; Breast Neoplasms/therapy ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Cell Line, Tumor ; Colorectal Neoplasms/immunology ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/therapy ; Diet, Ketogenic/methods ; Energy Metabolism/drug effects ; Energy Metabolism/genetics ; Enhancer of Zeste Homolog 2 Protein/genetics ; Enhancer of Zeste Homolog 2 Protein/immunology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immunotherapy/methods ; MARVEL Domain-Containing Proteins/genetics ; MARVEL Domain-Containing Proteins/immunology ; Mice ; Mice, Inbred C57BL ; Mice, Nude ; Pyrones/pharmacology ; Signal Transduction ; Survival Analysis ; Thiophenes/pharmacology
Czasopismo naukowe
Tytuł :
[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors].
Autorzy :
El Hazzaz R; Gustave-Roussy, hôpital de jour, département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Centre hospitalier universitaire Hassan II, service d'oncologie médicale, BP 1835 Atlas, avenue Hassan II, Fès 30050, Maroc.
Kfoury M; Gustave-Roussy, hôpital de jour, département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Lavaud P; Gustave-Roussy, hôpital de jour, département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Marabelle A; Gustave-Roussy, département d'innovation thérapeutique et essais précoces (DITEP), 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Champiat S; Gustave-Roussy, département d'innovation thérapeutique et essais précoces (DITEP), 114, rue Édouard-Vaillant, 94805 Villejuif, France.
Mellas N; Centre hospitalier universitaire Hassan II, service d'oncologie médicale, BP 1835 Atlas, avenue Hassan II, Fès 30050, Maroc.
Besse B; Gustave-Roussy, hôpital de jour, département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Paris-Saclay University, 91400 Orsay, France.
Massard C; Gustave-Roussy, département d'innovation thérapeutique et essais précoces (DITEP), 114, rue Édouard-Vaillant, 94805 Villejuif, France; Paris-Saclay University, 91400 Orsay, France.
Geraud A; Gustave-Roussy, hôpital de jour, département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif, France; Gustave-Roussy, département d'innovation thérapeutique et essais précoces (DITEP), 114, rue Édouard-Vaillant, 94805 Villejuif, France. Electronic address: .
Pokaż więcej
Transliterated Title :
Impact de l’utilisation de la corticothérapie systémique sur l’efficacité des inhibiteurs de points de contrôle immunitaire.
Źródło :
Bulletin du cancer [Bull Cancer] 2021 Jun; Vol. 108 (6), pp. 635-642. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
B7-H1 Antigen*
CTLA-4 Antigen*
Immunotherapy, Adoptive*
Adrenal Cortex Hormones/*pharmacology
Immune Checkpoint Inhibitors/*therapeutic use
Chromatin/drug effects ; Drug Interactions ; Humans ; Transcription, Genetic/drug effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Autorzy :
Sun MM; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.
Kelly SP; American Academy of Ophthalmology, San Francisco, California.
Mylavarapu Bs AL; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.
Holland GN; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.
Coleman AL; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California; Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California.
Yu F; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.
Hsu Ms S; American Academy of Ophthalmology, San Francisco, California.
Lum F; American Academy of Ophthalmology, San Francisco, California.
Gordon LK; Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California. Electronic address: .
Pokaż więcej
Źródło :
Ophthalmology [Ophthalmology] 2021 Jun; Vol. 128 (6), pp. 910-919. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Registries*
Antibodies, Monoclonal, Humanized/*adverse effects
CTLA-4 Antigen/*immunology
Immunotherapy/*adverse effects
Ipilimumab/*adverse effects
Uveitis, Anterior/*chemically induced
Academies and Institutes ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/adverse effects ; CTLA-4 Antigen/antagonists & inhibitors ; Electronic Health Records ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Incidence ; Male ; Middle Aged ; Ophthalmology ; Programmed Cell Death 1 Receptor ; Retrospective Studies ; United States/epidemiology ; Uveitis, Anterior/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.
Autorzy :
Ali NA; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, The British University in Egypt (BUE), El Sherouk, Cairo, Egypt.
Hamdy NM; Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, 11566, Egypt. .
Gibriel AA; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, The British University in Egypt (BUE), El Sherouk, Cairo, Egypt.; Faculty of Pharmacy, Center of Drug Research and Development (CDRD), BUE, El Sherouk, Cairo, Egypt.
El Mesallamy HO; Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, 11566, Egypt. .; Biochemistry Department, Faculty of Pharmacy, Sinai University, Kantara, Egypt. .
Pokaż więcej
Źródło :
Archives of virology [Arch Virol] 2021 Jun; Vol. 166 (6), pp. 1643-1651. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji :
Journal Article
MeSH Terms :
CTLA-4 Antigen/*metabolism
Carcinoma, Hepatocellular/*virology
Hepatitis C/*complications
Liver Neoplasms/*virology
STAT4 Transcription Factor/*metabolism
Tumor Suppressor Proteins/*metabolism
Adult ; Aged ; CTLA-4 Antigen/genetics ; Case-Control Studies ; Cohort Studies ; Female ; Hepacivirus ; Humans ; Male ; Middle Aged ; Mutation ; STAT4 Transcription Factor/genetics ; Tumor Suppressor Proteins/genetics ; Viral Load
Czasopismo naukowe
Tytuł :
Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody.
Autorzy :
Azuma T; Division of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashinodai, Fuchu, Tokyo, 183-8524, Japan. .; Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo, 183-8524, Japan. .
Takeuchi T; Division of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki-City, Kanagawa, 211-8510, Japan.
Matayoshi Y; Division of Urology, Tomishiro Central Hospital, 25 Ueda, Tomigusuku, Okinawa, 901-0243, Japan.
Namiki S; Division of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashinodai, Fuchu, Tokyo, 183-8524, Japan.
Obara T; Division of Thoracic Surgery, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashinodai, Fuchu, Tokyo, 183-8524, Japan.
Imamura K; Division of Surgery, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashinodai, Fuchu, Tokyo, 183-8524, Japan.
Takamori M; Division of Respiratory Medicine and Medical Oncology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashinodai, Fuchu, Tokyo, 183-8524, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 May 13; Vol. 11 (1), pp. 10264. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article
MeSH Terms :
Alanine Transaminase/*analysis
CTLA-4 Antigen/*antagonists & inhibitors
Programmed Cell Death 1 Receptor/*antagonists & inhibitors
Adult ; Aged ; Aged, 80 and over ; Alanine Transaminase/blood ; Biomarkers, Pharmacological/blood ; CTLA-4 Antigen/immunology ; Female ; Humans ; Immunotherapy/methods ; Liver/pathology ; Liver Regeneration ; Lymphocyte Count ; Male ; Middle Aged ; Neoplasms/immunology ; Neoplasms/therapy ; Programmed Cell Death 1 Receptor/immunology ; ROC Curve ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
Autorzy :
Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, Australia; Department of Medical Oncology, Austin Health, Melbourne, Australia. Electronic address: .
Kee D; Department of Medical Oncology, Austin Health, Melbourne, Australia; Department of Medical Oncology, Peter McCallum Cancer Centre, Melbourne, Australia.
Markman B; Department of Medical Oncology, Alfred Health, Melbourne, Australia; Monash University, Melbourne, Australia.
Carlino MS; Blacktown Hospital and the University of Sydney, Sydney, Australia.
Underhill C; Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, Australia.
Palmer J; Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Australia.
Power D; ThermoFisher Scientific Ltd.
Cebon J; Olivia Newton-John Cancer Research Institute, Melbourne, Australia; Department of Medical Oncology, Austin Health, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Australia.
Behren A; Olivia Newton-John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Australia.
Pokaż więcej
Źródło :
Cancer cell [Cancer Cell] 2021 May 10; Vol. 39 (5), pp. 592-593. Date of Electronic Publication: 2021 Apr 29.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*/methods
CTLA-4 Antigen/*immunology
Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*therapy
Biomarkers, Tumor/immunology ; CTLA-4 Antigen/metabolism ; Carcinoma, Non-Small-Cell Lung/immunology ; Humans ; Lung Neoplasms/immunology
Raport
Tytuł :
Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86-Positive B Cell Malignancies.
Autorzy :
Lin S; Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.; Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Guangzhou, China.; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Cheng L; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Ye W; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Li S; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Zheng D; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Qin L; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Wu Q; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Long Y; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Lin S; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Wang S; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Huang G; Department of Respiratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Li P; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Yao Y; State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Sun X; Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.; Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Guangzhou, China.; Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Apr 02; Vol. 12, pp. 642528. Date of Electronic Publication: 2021 Apr 02 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen*
Lymphoma, B-Cell*
Receptors, Chimeric Antigen*
Immunotherapy, Adoptive/*methods
Animals ; CD28 Antigens ; CD3 Complex ; Humans ; Mice ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
Autorzy :
Chang HW; BioAtla, Inc., San Diego, CA 92121.
Frey G; BioAtla, Inc., San Diego, CA 92121.
Liu H; BioAtla, Inc., San Diego, CA 92121.
Xing C; BioAtla, Inc., San Diego, CA 92121.
Steinman L; Stanford University School of Medicine, Stanford University, Stanford, CA 94305 .
Boyle WJ; BioAtla, Inc., San Diego, CA 92121.
Short JM; BioAtla, Inc., San Diego, CA 92121; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Mar 02; Vol. 118 (9).
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal/*pharmacology
Antibodies, Monoclonal, Humanized/*pharmacology
Antibodies, Neoplasm/*pharmacology
B7-H1 Antigen/*antagonists & inhibitors
CTLA-4 Antigen/*antagonists & inhibitors
Colonic Neoplasms/*therapy
Immunotherapy/*methods
5'-Nucleotidase/antagonists & inhibitors ; 5'-Nucleotidase/genetics ; 5'-Nucleotidase/immunology ; Animals ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal, Humanized/chemistry ; Antibodies, Neoplasm/chemistry ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; Bicarbonates/chemistry ; CD3 Complex/antagonists & inhibitors ; CD3 Complex/genetics ; CD3 Complex/immunology ; CTLA-4 Antigen/genetics ; CTLA-4 Antigen/immunology ; Cell Adhesion Molecules/antagonists & inhibitors ; Cell Adhesion Molecules/genetics ; Cell Adhesion Molecules/immunology ; Colonic Neoplasms/genetics ; Colonic Neoplasms/immunology ; Colonic Neoplasms/pathology ; Epithelial Cell Adhesion Molecule/antagonists & inhibitors ; Epithelial Cell Adhesion Molecule/genetics ; Epithelial Cell Adhesion Molecule/immunology ; GPI-Linked Proteins/antagonists & inhibitors ; GPI-Linked Proteins/genetics ; GPI-Linked Proteins/immunology ; Gene Expression ; Humans ; Hydrogen Sulfide/chemistry ; Hydrogen-Ion Concentration ; Macaca fascicularis ; Mice ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/genetics ; Neoplasm Proteins/immunology ; Protein Engineering/methods ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/immunology ; T-Lymphocytes, Cytotoxic/drug effects ; T-Lymphocytes, Cytotoxic/immunology ; T-Lymphocytes, Cytotoxic/pathology ; Tumor Burden/drug effects ; Tumor Microenvironment/drug effects ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Cytotoxic T-lymphocyte Antigen-4 ( CTLA-4 ) Gene Polymorphism (rs3087243) Is Related to Risk and Survival in Patients With Colorectal Cancer.
Autorzy :
VAN Nguyen S; Department of Medical Laboratory, Danang University of Medical Technology and Pharmacy, Danang, Vietnam.
Shamoun L; Department of Laboratory Medicine and Pathology, Region Jönköping County, Jönköping, Sweden.; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Landerholm K; Department of Surgery, Region Jönköping County, Jönköping, Sweden; Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.
Andersson RE; Department of Surgery, Region Jönköping County, Jönköping, Sweden; Department of Biomedical and Clinical Science, Linköping University, Linköping, Sweden.
Wagsater D; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Dimberg J; Department of Natural Science and Biomedicine, School of Health and Welfare, Jönköping University, Jönköping, Sweden .
Pokaż więcej
Źródło :
In vivo (Athens, Greece) [In Vivo] 2021 Mar-Apr; Vol. 35 (2), pp. 969-975.
Typ publikacji :
Journal Article
MeSH Terms :
CTLA-4 Antigen*/genetics
Colorectal Neoplasms*/genetics
Genetic Predisposition to Disease*
Gene Frequency ; Genotype ; Humans ; Polymorphism, Single Nucleotide ; Sweden
Czasopismo naukowe
Tytuł :
CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility.
Autorzy :
Abramiuk M; Department of Gynecological Oncology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland.
Bębnowska D; Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
Hrynkiewicz R; Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.
Polak PNG; Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland.; Department of Gynecological Oncology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland.
Kotarski J; Department of Gynecological Oncology and Gynecology, Medical University of Lublin, 20-081 Lublin, Poland.
Roliński J; Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.
Grywalska E; Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.
Pokaż więcej
Źródło :
Cells [Cells] 2021 Feb 25; Vol. 10 (3). Date of Electronic Publication: 2021 Feb 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CTLA-4 Antigen/*metabolism
Endometriosis/*metabolism
Infertility/*metabolism
Inflammation/*metabolism
Adult ; Antigens, CD19/metabolism ; Ascitic Fluid/metabolism ; B-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; CTLA-4 Antigen/blood ; Case-Control Studies ; Chronic Disease ; Endometriosis/blood ; Endometriosis/immunology ; Female ; Humans ; Infertility/blood ; Infertility/immunology ; Inflammation/blood ; Inflammation/immunology ; Middle Aged ; Pelvic Pain/blood ; Pelvic Pain/complications ; Pelvic Pain/immunology ; Solubility ; T-Lymphocytes/immunology ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies